Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
11.07
+0.02 (0.18%)
At close: Sep 16, 2026, 4:00 PM EDT
11.04
-0.03 (-0.27%)
After-hours: Sep 16, 2026, 4:10 PM EDT

Benitec Biopharma Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Benitec Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $24.33. The average 1-year stock price forecast is 119.78% higher than the current stock price, while the lowest is $17 (+53.57%) and the highest is $32 (+189.07%).

Price Target: $24.33 (+119.78%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$17$24.33$24.5$32
Change+53.57%+119.78%+121.32%+189.07%

Analyst Ratings

The average analyst rating for Benitec Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy666566
Buy111111
Hold000000
Sell000000
Strong Sell000000
Total777677

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
TD Cowen
TD Cowen
Buy
Maintains
n/a
BuyMaintainsn/an/aSep 16, 2026
Evercore ISI
Evercore ISI
Buy
Maintains
$25
BuyMaintains$25+125.84%Sep 15, 2026
Wedbush
Wedbush
Buy
Reiterates
$16$17
BuyReiterates$16$17+53.57%Sep 15, 2026
Guggenheim
Guggenheim
Hold
Downgrades
n/a
HoldDowngradesn/an/aJun 10, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$32
BuyReiterates$32+189.07%May 26, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
6.29
EPS Next Year
23.12
from 6.29
Increased by 267.57%
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingJun 30, 2022Jun 30, 2023Jun 30, 2024Jun 30, 2025Jun 30, 2026Jun 30, 2027
Revenue
73.00K75.00K----
Gross Profit
64.00K75.00K108.00K---
Gross Margin
87.67%100.00%---85.00%
Operating Income
-17.85M-19.08M-22.49M-41.77M-51.19M-62.22M
Net Income
-18.21M-19.56M-21.75M-37.92M-45.55M-57.35M
EPS
-----6.29
Forward PE
-----1.76
Free Cash Flow
-8.72M-10.19M-11.68M-11.46M-2.75M-40.32M
No. Analysts
-----6
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202720282029
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20282029
High-
Avg-
Low-

EPS Forecast

EPS202720282029
High6.29
Avg6.29
Low6.29

EPS Growth

EPS Growth20282029
High
267.6%
Avg
267.6%
Low
267.6%